Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jun 13;28(12):2547-2554.
doi: 10.1158/1078-0432.CCR-21-3807.

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Gontran Verset  1 , Ivan Borbath  2 , Mark Karwal  3 , Chris Verslype  4 , Hans Van Vlierberghe  5 , Adel Kardosh  6 , Vittorina Zagonel  7 , Per Stal  8 , Debashis Sarker  9 , Daniel H Palmer  10 , Arndt Vogel  11 , Julien Edeline  12 , Stephane Cattan  13 , Masatoshi Kudo  14 , Ann-Lii Cheng  15 , Sadahisa Ogasawara  16 , Bruno Daniele  17 , Stephen L Chan  18 , Jennifer J Knox  19 , Shukui Qin  20 , Abby B Siegel  21 , Michael Chisamore  21 , Ken Hatogai  21 , Anran Wang  21 , Richard S Finn #  22 , Andrew X Zhu #  23   24
Affiliations
Clinical Trial

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Gontran Verset et al. Clin Cancer Res. .

Abstract

Purpose: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior systemic therapy.

Patients and methods: KEYNOTE-224 was an open-label, multicountry phase II trial. Eligible patients in cohort 2 had advanced HCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for ≤2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease control rate (DCR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety/tolerability.

Results: Between September 4, 2018, and February 20, 2019, 51 patients were allocated in cohort 2. The median time from the first dose to data cutoff (January 19, 2021) was 27 months (range, 23-29). ORR was 16% [95% confidence interval (CI), 7-29] and was similar across key subgroups. Median DOR was 16 months (range, 3-24+), and DCR was 57%. The median PFS was 4 months (95% CI, 2-8), and median TTP was 4 months (95% CI, 3-9). Median OS was 17 months (95% CI, 8-23). Grade ≥3 treatment-related adverse events occurred in 16% of patients.

Conclusions: In patients with advanced HCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC.

Trial registration: ClinicalTrials.gov NCT03867084 NCT04246177 NCT02702414.

PubMed Disclaimer

Figures

Figure 1. Subgroup analyses of objective response. *All prespecified except the analyses by alcohol use.
Figure 1.
Subgroup analyses of objective response. *All prespecified except the analyses by alcohol use.
Figure 2. Characteristics of tumor response to pembrolizumab. A, Best percentage change from baseline in target lesion in patients without viral etiology (green) and those with viral etiology (blue). Stars indicate patients with a confirmed response by central imaging review. B, Duration of study treatment and response in responders. Each horizontal line represents 1 patient. The end of the bar represents the dates of the last radiology imaging assessment.
Figure 2.
Characteristics of tumor response to pembrolizumab. A, Best percentage change from baseline in target lesion in patients without viral etiology (green) and those with viral etiology (blue). Stars indicate patients with a confirmed response by central imaging review. B, Duration of study treatment and response in responders. Each horizontal line represents 1 patient. The end of the bar represents the dates of the last radiology imaging assessment.
Figure 3. Kaplan–Meier curves for PFS (A), and OS (B).
Figure 3.
Kaplan–Meier curves for PFS (A) and OS (B).
See this image and copyright information in PMC

Comment in

  • Clin Cancer Res. 28:2475.
  • Clin Cancer Res. 28:2475.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. - PubMed
    1. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683–91. - PMC - PubMed
    1. Park J-W, Chen M, Colombo M, Roberts LR, Schwartz M, Chen P-J, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155–66. - PMC - PubMed
    1. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. - PubMed

Publication types

MeSH terms

Substances

Associated data